150 related articles for article (PubMed ID: 38213189)
21. Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B.
Jung YW; Kim M; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kim SU
J Korean Med Sci; 2020 May; 35(17):e104. PubMed ID: 32356416
[TBL] [Abstract][Full Text] [Related]
22. Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
Liu Z; Zhao Z; Ma X; Liu S; Xin Y
BMC Gastroenterol; 2023 Nov; 23(1):384. PubMed ID: 37950196
[TBL] [Abstract][Full Text] [Related]
23. Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B.
Lim YS; Chan HLY; Ahn SH; Seto WK; Ning Q; Agarwal K; Janssen HLA; Pan CQ; Chuang WL; Izumi N; Fung S; Shalimar ; Brunetto M; Hui AJ; Chang TT; Lim SG; Abramov F; Flaherty JF; Wang H; Yee LJ; Kao JH; Gane E; Hou J; Buti M
JHEP Rep; 2023 Oct; 5(10):100847. PubMed ID: 37771546
[TBL] [Abstract][Full Text] [Related]
24. Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation.
Chiu SM; Chang KC; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
Dig Dis Sci; 2023 Feb; 68(2):665-675. PubMed ID: 35976597
[TBL] [Abstract][Full Text] [Related]
25. Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study.
Ogawa E; Nakamuta M; Koyanagi T; Ooho A; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Satoh T; Takahashi K; Azuma K; Yamashita N; Yamashita N; Sugimoto R; Amagase H; Kuniyoshi M; Ichiki Y; Morita C; Kato M; Shimoda S; Nomura H; Hayashi J;
Hepatol Int; 2022 Apr; 16(2):282-293. PubMed ID: 35075593
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of tenofovir in nucleos(t)ide-naïve patients with genotype C chronic hepatitis B in real-life practice.
Kim JH; Jung SW; Byun SS; Shin JW; Park BR; Kim MH; Kim CJ; Park NH
Int J Clin Pharm; 2015 Dec; 37(6):1228-34. PubMed ID: 26364195
[TBL] [Abstract][Full Text] [Related]
27. Tenofovir Alafenamide for Pregnant Chinese Women With Active Chronic Hepatitis B: A Multicenter Prospective Study.
Zeng QL; Zhang HX; Zhang JY; Huang S; Li WZ; Li GM; Pan YJ; Feng YH; Li ZQ; Zhang GF; Xu JH; Lin WB; Xu GH; Liu N; Zhang GQ; Li GT; Li W; Zeng YL; Song N; Wang M; Zhang DW; Chen ZM; Cui GL; Li J; Lv J; Liu YM; Liang HX; Sun CY; Zhou YH; Yu ZJ; Wang FS
Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2826-2837.e9. PubMed ID: 34902570
[TBL] [Abstract][Full Text] [Related]
28. Comparison of tenofovir alafenamide and entecavir for hepatitis B virus
Peng W; Gu H; Jiang C; Liu J; Zhang J; Fu L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Feb; 47(2):194-201. PubMed ID: 35545409
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients.
He J; Guo Y; Zhang Y; Han J; Chen J; Jia Y; Ma Z; Wu J; Zhang S; Li F; Mao R; Zhang J
Infect Drug Resist; 2023; 16():3929-3941. PubMed ID: 37361938
[TBL] [Abstract][Full Text] [Related]
30. Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.
Ogawa E; Nakamuta M; Koyanagi T; Ooho A; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Satoh T; Takahashi K; Azuma K; Yamashita N; Yamashita N; Sugimoto R; Amagase H; Kuniyoshi M; Ichiki Y; Morita C; Kato M; Shimoda S; Nomura H; Hayashi J;
Aliment Pharmacol Ther; 2022 Aug; 56(4):713-722. PubMed ID: 35735794
[TBL] [Abstract][Full Text] [Related]
31. First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alefenamide.
Pan CQ; Afdhal NH; Ankoma-Sey V; Bae H; Curry MP; Dieterich D; Frazier L; Frick A; Hann HW; Kim WR; Kwo P; Milligan S; Tong MJ; Reddy KR
Hepatol Commun; 2022 Aug; 6(8):1881-1894. PubMed ID: 35445803
[TBL] [Abstract][Full Text] [Related]
32. [Clinical efficacy analysis of TMF for the treatment of hyperviremia HBeAg-positive chronic hepatitis B patients with incomplete response to first-line oral antiviral nucleos(t)ide analogues].
Sheng QJ; Han C; Li YW; Zhang C; Dou XG; Ding Y
Zhonghua Gan Zang Bing Za Zhi; 2023 Mar; 31(3):252-257. PubMed ID: 37137850
[No Abstract] [Full Text] [Related]
33. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.
Li J; Hu C; Chen Y; Zhang R; Fu S; Zhou M; Gao Z; Fu M; Yan T; Yang Y; Li J; Liu J; Chen T; Zhao Y; He Y
BMC Infect Dis; 2021 Jun; 21(1):567. PubMed ID: 34126939
[TBL] [Abstract][Full Text] [Related]
34. Tenofovir Alafenamide Fumarate, Tenofovir Disoproxil Fumarate and Entecavir: Which is the Most Effective Drug for Chronic Hepatitis B? A Systematic Review and Meta-analysis.
Ma X; Liu S; Wang M; Wang Y; Du S; Xin Y; Xuan S
J Clin Transl Hepatol; 2021 Jun; 9(3):335-344. PubMed ID: 34221919
[TBL] [Abstract][Full Text] [Related]
35. Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection.
Kim SH; Cho EJ; Jang BO; Lee K; Choi JK; Choi GH; Lee JH; Yu SJ; Kim YJ; Lee YB; Yoon JH; Kim JW; Jeong SH; Jang ES
Liver Int; 2022 Feb; 42(2):320-329. PubMed ID: 34679254
[TBL] [Abstract][Full Text] [Related]
36. No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection.
Cathcart AL; Chan HL; Bhardwaj N; Liu Y; Marcellin P; Pan CQ; Shalimar ; Buti M; Cox S; Parhy B; Zhou E; Martin R; Chang S; Lin L; Flaherty JF; Kitrinos KM; Gaggar A; Izumi N; Lim YS
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30038044
[TBL] [Abstract][Full Text] [Related]
37. HBV relapse rates in patients who discontinue tenofovir disoproxil fumarate with or without switching to tenofovir alafenamide.
Chen CH; Jeng WJ; Hu TH; Liu YC; Wang JH; Hung CH; Lu SN; Chien RN
Dig Liver Dis; 2023 Jun; 55(6):771-777. PubMed ID: 36737315
[TBL] [Abstract][Full Text] [Related]
38. Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy.
Ogawa E; Furusyo N; Nguyen MH
Drug Des Devel Ther; 2017; 11():3197-3204. PubMed ID: 29158666
[TBL] [Abstract][Full Text] [Related]
39. Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials.
Wong WWL; Pechivanoglou P; Wong J; Bielecki JM; Haines A; Erman A; Saeed Y; Phoon A; Tadrous M; Younis M; Rayad NZ; Rac V; Janssen HLA; Krahn MD
Syst Rev; 2019 Aug; 8(1):207. PubMed ID: 31426837
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study.
Farag MS; Fung S; Tam E; Doucette K; Wong A; Ramji A; Conway B; Cooper C; Tsoi K; Wong P; Sebastiani G; Brahmania M; Haylock-Jacobs S; Coffin CS; Hansen BE; Janssen HLA
J Viral Hepat; 2021 Jun; 28(6):942-950. PubMed ID: 33749086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
